Icotrokinra vs Lanreotide
Overview
Icotrokinra is primarily a immune support peptide, while Lanreotide is used for hormonal.
This page compares Icotrokinra and Lanreotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Icotrokinra | Lanreotide | |
|---|---|---|
| Category | Immune Support | Hormonal |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | — | 60-120 mg |
| Frequency | — | every 4 weeks |
| Reported benefits | — | suppression of excess growth hormone and IGF-1 in acromegaly, improved progression-free survival in GEP-NETs, reduction of carcinoid syndrome symptoms, inhibition of multiple GI and pancreatic hormones |
| Reported side effects | — | diarrhea, cholelithiasis, abdominal pain, hyperglycemia, bradycardia, injection site reactions, nausea, hypertension, headache, thyroid function decreases |
Key differences
Primary use. Icotrokinra is categorised under Immune Support, while Lanreotide falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Icotrokinra: FDA-approved. Lanreotide: FDA-approved.
Dosing. Typical dosing for Icotrokinra is not catalogued. Lanreotide is typically dosed at 60-120 mg (every 4 weeks).
Can you stack them?
Some protocols combine peptides, but stacking Icotrokinra and Lanreotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Icotrokinra and Lanreotide?
- Icotrokinra is primarily a immune support peptide, while Lanreotide is used for hormonal. Icotrokinra is FDA-approved for one or more indications, whereas Lanreotide is FDA-approved for one or more indications.
- What is Icotrokinra used for?
- Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis.
- What is Lanreotide used for?
- FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome.
- Can you take Icotrokinra and Lanreotide together?
- Some users combine peptides within a single protocol, but stacking Icotrokinra and Lanreotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Icotrokinra or Lanreotide FDA-approved?
- Icotrokinra is FDA-approved for one or more indications. Lanreotide is FDA-approved for one or more indications.
Read the full articles
- Icotrokinra — full monograph: mechanism, research, dosing & references
- Lanreotide — full monograph: mechanism, research, dosing & references